Related Experiment Video

Updated: Jun 2, 2026

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major
08:17

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

Leishmania major MAP kinase 10 is protective against experimental L. major infection

Sangeeta Kumari1, Sushma Singh, Bhaskar Saha

  • 1National Centre for Cell Science, Ganeshkhind, Pune 411007, India.

Vaccine
|April 30, 2011
PubMed

Insights

Developing a vaccine against leishmaniasis is crucial. L. major MAP kinase 10 (LmjMAPK10) shows promise as a vaccine candidate, inducing significant protection in mice against leishmaniasis.

Area of Science:

  • Parasitology
  • Immunology
  • Vaccine Development

Background:

  • Leishmaniasis, caused by Leishmania parasites, results in severe disease with significant global socio-economic impact.
  • An effective vaccine against leishmaniasis is urgently needed due to the disease's disfiguring nature, morbidity, and mortality.
  • Leishmania parasites reside and replicate within macrophages, presenting a challenge for immune system targeting.

Purpose of the Study:

  • To evaluate the immunogenicity and protective efficacy of L. major MAP kinase 10 (LmjMAPK10) as a potential vaccine candidate.
  • To assess the immune response induced by LmjMAPK10 in a susceptible mouse model.
  • To determine if LmjMAPK10 immunization confers resistance against Leishmania infection.

Main Methods:

  • Immunization of BALB/c mice (a susceptible strain) with L. major MAP kinase 10 (LmjMAPK10) using DNA, protein, or a combination of both.
  • Challenging immunized mice with Leishmania parasites to assess protective efficacy.
  • Analyzing the immune response, specifically Th1/Th2 profiles, following immunization and challenge.

Main Results:

  • LmjMAPK10 priming provided significant protection against Leishmania infection in BALB/c mice.
  • The observed resistance correlated with a mixed Th1/Th2 immune response.
  • Both DNA and protein formulations of LmjMAPK10, as well as their combination, elicited protective immunity.

Conclusions:

  • L. major MAP kinase 10 (LmjMAPK10) demonstrates significant potential as a vaccine candidate against leishmaniasis.
  • Immunization with LmjMAPK10 induces a protective immune response characterized by mixed Th1/Th2 activity.
  • Further development of LmjMAPK10-based vaccines is warranted for combating leishmaniasis.

More Related Videos

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...